What Happened

GSK announced up to 1,217 job cuts in Belgium as part of a global cost-saving program targeting £1.9 billion in annual savings by 2029. The layoffs, first reported by Belgian newspaper L'Echo, span R&D, manufacturing, and support functions. GSK cited over-capacity in its vaccine supply chain and the need to reallocate resources to priority late-stage pipeline projects.

Who Is Affected

GSK employs approximately 8,500 people across three main Belgian vaccine sites: Gembloux (vaccine storage), Wavre (headquarters and manufacturing), and Rixensart (vaccine R&D). The proposed changes will affect roles in R&D, manufacturing, and global support functions. This follows similar restructuring in Poland and is part of a three-year global program announced in July.

Market Impact

GSK's cost-saving program emphasizes better procurement and simplification of support functions, with CEO Luke Miels stating that about 45% of required savings will come from areas 'not on the frontline of our labs,' including systems, consultants, partners, and support functions. This creates opportunities for:

• Procurement and sourcing efficiency vendors
• HR transition and outsourcing services
• R&D software and CRO/CDMO partners for reprioritized pipeline
• Manufacturing optimization and supply chain solutions

What to Watch

Monitor GSK for further layoffs in other countries as the global program rolls out. The aggressive procurement targets may signal a shake-up of existing vendor relationships, while R&D reprioritization could shift spend toward new therapeutic areas. Belgium is the second country affected after Poland, suggesting more regional announcements are likely.

Related coverage

• GSK plans 1,200+ layoffs at Belgium sites as $2.5B restructure gains momentum
• GSK pledges $800M to add biologics production capabilities in Pennsylvania
• Enanta Pharmaceuticals lays off 37 employees ahead of key antiviral and immunology readouts
• Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data